Best of ASCO 2023, Boise

Boise, ID US
July 15, 2023 to July 16, 2023

This CME-accredited oncology conference, Best of ASCO 2023, Boise, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2023 ASCO® Annual Meeting (ASCO2023) in June 2023. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2023 into clinical contexts and discuss how the results may change the current standard of care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

 

HOTEL RESERVATION 

A limited number of rooms have been reserved at the Riverside Hotel, Boise at a discounted rate of $215/night for the participants of this conference.

Please call 208-343-1871 and ask for the Best of American Society of Clinical Oncology group rate or follow the link below:

https://www.bestwestern.com/en_US/book/hotel-rooms.13062.html?groupId=1Y8ID8X7

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2023 and discuss their application in clinical settings

 

Course summary
Available credit: 
  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
Course opens: 
01/24/2023
Course expires: 
09/16/2023
Event starts: 
07/15/2023 - 8:00am PDT
Event ends: 
07/16/2023 - 12:15pm PDT
Cost:
$350.00

Conference chairs: Dr. Mark Lewis & Dr. Christos Vaklavas

DAY 1

All times below are listed in Mountain Daylight Time (MDT)

07:00 – 08:00 AM: REGISTRATION

08:00 - 08:15 AM: Opening Remarks


08:15 AM – 09:45 AM: HEMATOLOGIC MALIGNANCIES SESSION

08:15 - 08:45 AM: MDS/leukemias- Prashant Sharma, MD

08:45 - 09:15 AM: Multiple myeloma- Douglas Sborov, MD, MS

09:15 - 09:45 AM: Lymphoma & CLL- Wayne Ormsby, MD


09:45 – 10:00 AM: BREAK


10:00 – 11:00 AM: THORACIC ONCOLOGY SESSION
Moderator: Siddhartha Devarakonda, MD

10:00 - 10:30 AM: Early-stage lung cancer- Wallace L. Akerley, MD

10:30 - 11:00 AM: Metastatic lung cancer- Sonam Puri, MD


11:00 - 12:00 PM: Case-based presentation


12:00 – 13:00 PM: LUNCH


13:00 – 15:00 PM: GENERAL ONCOLOGY SESSION
Moderator: Andrew Scott Pierson, MD

13:00 - 13:30 PM: Sarcoma updates- Vaia Florou, MD

13:30 - 14:00 PM: Brain tumor updates- Rachna Malani, MD

14:00 - 14:30 PM: Head neck cancer- Katie Kerrigan, DO

14:30 - 15:00 PM: Gynecologic cancer- Kristen Kelley, MD


15:00 – 15:30 BREAK


15:30 – 17:00 PM: GENITOURINARY CANCER SESSION
Moderator: Ian Qureshi, DO

15:30 - 16:00 PM: Prostate cancer-  David Gill, MD

16:00 - 16:30 PM: Bladder cancer- Umang Swami, MD

16:30 - 17:00 PM: Kidney cancer- Benjamin Maughan, MD


DAY 2

07:00 – 08:00 AM: REGISTRATION AND BREAKFAST


08:00 – 08:30 AM: SKIN CANCER
Moderator: Christos Vaklavas, MD

08:00 - 08:30 AM: Melanoma update- Caroline Nebhan, MD


08:30 - 09:00 AM: Case-based presentation- Fengting Yan, MD, FACP


09:00 TO 10:30 AM: GI CANCER SESSION
Moderator: Stephanie Hodson, MD

09:00 - 09:30 AM: Colorectal cancer- Mark Lewis, MD

09:30 - 10:00 AM: Hepatobiliary and pancreatic malignancies- Ignacio Garrido-Laguna, MD, PhD

10:00 - 10:30 AM: Upper GI cancer- Glynn Gilcrease III, MD


10:30 TO 10:45 AM: BREAK


10:45 TO 12:15 PM: BREAST CANCER SESSION
Moderator: Banu E. Symington, MD

10:45 - 11:15 AM: Early-stage breast cancer- Mei Wei, MD

11:15 - 11:45 AM: Metastatic breast cancer 1 (hormone receptor positive)- Shivani Shinde, MD

11:45 - 12:15 PM: Metastatic breast cancer 2 (HER2 +ve and triple negative breast cancer)- Christos Vaklavas, MD

The Riverside Hotel
2900 W Chinden Blvd
Boise, ID 83714
United States

ROOM RESERVATION 

A limited number of rooms have been reserved at the Riverside Hotel, Boise at a discounted rate of $215/night for the participants of this conference.

Please call 208-343-1871 and ask for the Best of American Society of Clinical Oncology group rate or follow the link below:

https://www.bestwestern.com/en_US/book/hotel-rooms.13062.html?groupId=1Y8ID8X7

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Mark Lewis, M.D.

has a financial relationship (Professional Services) with Natera;.
has a financial relationship (Professional Services) with Medscape;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with AstraZeneca/Daiichi Sankyo;.
has a financial relationship (Professional Services) with HalioDx;.
has a financial relationship (Professional Services) with TerSera;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Foundation Medicine;.
has a financial relationship (Professional Services) with QED;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with H3 Biomedicine;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Financial Support) with SeaGen;.
has a financial relationship (Employment) with Flatiron;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with CytomX;.
Speaker/Topic Presenter(s)

Wallace Akerley, MD

has no relevant financial relationships to disclose at this time.

Vaia Florou

has a financial relationship (Other) with Incyte ;.
has a financial relationship (Other) with Deciphera;.

Ignacio Garrido-Laguna

has a financial relationship (Grant Or Contract) with BridgeBio Pharma , Genentech;.
has a financial relationship (Grant Or Contract) with ABM Therapeutics;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline ;.
has a financial relationship (Grant Or Contract) with Sotio;.
has a financial relationship (Grant Or Contract) with Sumitomo;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Tango Therapeutics;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with MedImmune;.
has a financial relationship (Grant Or Contract) with Revolution Medicine;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Pfizer;.

G. Weldon Gilcrease

has no relevant financial relationships to disclose at this time.

David Gill, MD

has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Myovant;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with AstraZeneca;.

Kristen Kelley, MD

has no relevant financial relationships to disclose at this time.

Katie Kerrigan, DO

has no relevant financial relationships to disclose at this time.

Rachna Malani, MD

has no relevant financial relationships to disclose at this time.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with Janssen;.

Caroline Nebhan, MD, PhD

has no relevant financial relationships to disclose at this time.

Wayne Ormsby, MD

has no relevant financial relationships to disclose at this time.

Sonam Puri, MD

has a financial relationship (Professional Services) with Jazz Pharmaceuticals ;.
has a financial relationship (Professional Services) with Pfizer ;.
has a financial relationship (Professional Services) with G1 therapeutics ;.

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with Arcellx;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Bristol Myer Squibb;.
has a financial relationship (Professional Services) with Sanofi;.

Prashant Sharma

has no relevant financial relationships to disclose at this time.

Shivani Shinde

has no relevant financial relationships to disclose at this time.

Umang Swami, MD, MS

has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Seattle Genetics;.
has a financial relationship (Other) with Exelixis;.

Mei Wei, MD

has a financial relationship (Other) with Gilead Science;.
Moderator(s)

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with Genetech;.
has a financial relationship (Other) with AZ;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Other) with Merus;.

Stephanie Hodson, MD

has a financial relationship (Independent contractor) with PRIME;.
has a financial relationship (Independent contractor) with PRIME;.

Andrew Pierson, MD

has no relevant financial relationships to disclose at this time.

Ian Qureshi

has a financial relationship (Professional Services) with Astra Zeneca;.

Banu Symington, MD

has no relevant financial relationships to disclose at this time.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported with an independent medical education grant from the following companies:

  • Novocure, Inc.
  • Seagen

Available Credit

  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.